Oncology

Human breast cancer cells stained for DNA
#Cancer research #Collaboration #DNA #NeoPhore #Oncology #Partnership #The Institute of Cancer Research

Immuno-oncology collaboration to develop new type of cancer drug

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Under a new strategic research collaboration, an ICR team led by Professor Chris Lord will investigate the effect of NeoPhore’s inhibitors on… Read More

#Business & Investment #News

Macrophage
#AACR 2023 #Cancer research #Macomics #Macrophages #Oncology #Tumour microenvironment (TME)

Benefits of reprogramming tumour macrophages presented at AACR

UK company Macomics presented data demonstrating its Enigmac macrophage drug discovery platform at the American Association for Cancer Research’s Annual Meeting (AACR) in Florida. The company uses macrophage-based approaches to develop novel precision medicines to target disease specific macrophage biology. Macrophages are key players… Read More

#Cancer Research #News

Scientist in laboratory
#AACR 2023 #Cancer research #Clinical trials #Immunotherapy #Oncology #Rare cancers

Trial results suggest new approaches to treat rare cancers

The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study… Read More

#Cancer Research #News #Trending News

Gene sequence
#AACR 2023 #Cancer research #Gene mutation #Genetics / genomics #Oncology #Whole genome sequencing

Exome sequencing proves current cancer risk testing is inadequate

Exome sequencing correctly identified individuals with cancer predisposition syndromes who would have been missed by current screening guidelines, according to results from the Tapestry clinical trial. Data presented at the AACR Annual Meeting 2023 showed that among individuals who consented to whole-exome sequencing and were identified… Read More

#Cancer Research #News #Trending News

Cancer cells
#AACR 2023 #Cancer research #Oncology #Paediatrics #Phase I trial #Solid tumours

Combo therapy may benefit some paediatric cancer patients

A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data. The results from the Phase I portion of the Phase I/II… Read More

#Cancer Research #News

Histology slides
#AACR 2023 #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer research #Machine learning #Oncology

AI can predict the risk of distant recurrence in endometrial cancer

An investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant recurrence in patients with endometrial cancer, according to findings presented at the AACR Annual Meeting 2023. Endometrial cancer is the most common type of uterine cancer. While patients with early-stage uterine… Read More

#Cancer Research #News #Trending News

Tumour microenvironment
#AACR 2023 #Avacta #Cancer research #Oncology #Preclinical development #Solid tumours

Data shows new therapy successfully targets solid tumours

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. Read More

#Cancer Research #News

Genetic sequencing in the lab
#Cancer research #Genetics / genomics #Next generation sequencing #Oncology #Personalised medicine #RNA sequencing #The Tecan Group #Webinar

Register now to learn how NGS is informing oncology drug discovery

Join this free webinar to learn about the biggest challenges and opportunities facing the next-generation sequencing (NGS) oncology space. Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend on April 24 at 7AM PST… Read More

Webinar date:
Brought to you by Tecan
#News

Teenage boy having vaccination
#AACR 2023 #Cancer research #HPV #Oncology #Vaccines

Awareness of the link between HPV and cancer has declined

Americans have become less aware that the human papillomavirus (HPV) causes cervical cancer in recent years, according to survey data presented at the AACR Annual Meeting 2023. Survey respondents also showed low awareness that HPV can cause anal, oral, and penile cancer. “Over 90%… Read More

#News

Myeloma cells
#AACR 2023 #Antibody #Cancer research #Immunotherapy #Myeloma #Oncology #T cell activation

Bispecific antibody has 90% response rate in multiple myeloma

Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual… Read More

#Cancer Research #News #Trending News

#Cancer research #CAR-T #Immunotherapy #Interview #Meet the Researcher #Oncology

Meet the researcher: John Maher, Leucid Bio

Listen to this article on the DDW Podcast: John Maher, Leucid Bio, tells Megan Thomas about his work and offers valuable advice to others in this field. MT: Where do you work, and can you tell us what you’re working on at the moment?… Read More

#Exclusive Content

Genetics
#AACR 2023 #Cancer research #Colorectal cancer #Genetics / genomics #Oncology

Patients of African heritage have fewer actionable mutations

Genomic profiling of patients who were treated for colorectal cancer showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry. These patients were also less likely to qualify for treatment with immunotherapy, according to data presented at the AACR Annual Meeting… Read More

#Cancer Research #News #Trending News

Medical research
#Cancer research #Clinical trial #Oncology #Phase I trial #Solid tumours #Totus Medicines

First patient dosed with PI3Kα inhibitor for solid tumours

Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The Totus Accel Platform is designed to be the first biosearch technology that scans, maps, and… Read More

#Cancer Research #News

Medical laboratory
#AACR 2023 #Cancer research #Cancer treatment #Oncology #Phase III trial #Rare cancers

Immune checkpoint inhibitor improved survival in rare cancer

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The results were presented at the AACR Annual Meeting 2023, held April 14-19 and… Read More

#Cancer Research #News

Lung cancer
#AACR 2023 #Cancer research #Cancer treatment #Lung cancer #Oncology #Phase III trial

Therapy represents ‘new treatment paradigm’ for lung cancer

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN… Read More

#Cancer Research #News #Trending News